68 results
8-K
EX-99.1
EQ
Equillium Inc
9 May 24
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
4:05pm
, and greater employee compensation expenses, which were partially offset by decreases in certain clinical study expenses and greater estimated Australian … to the Ono partnership, partially offset by greater R&D operating expenses.
Cash, cash equivalents and short-term investments totaled $32.3 million
8-K
EX-99.1
EQ
Equillium Inc
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
offset by increased clinical development expenses, primarily driven by the EQUATOR, EQ101 and EQ102 clinical studies.
General and administrative (G … , which were partially offset by greater audit and tax related professional fees.
Net loss for the fourth quarter of 2023 was $2.3 million, or $(0.07
8-K
EX-99.1
f0o0lsovpjwrfwdyh4r
8 Mar 24
Departure of Directors or Certain Officers
4:01pm
8-K
EX-99.2
kg2ljpti136k
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
424B5
npfr1 n2bd835
5 Oct 23
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.1
guchn6ggpyvsmr3dli
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
8-K
EX-99.1
6eces1g
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm
424B3
yfa8i9 01
10 Nov 22
Prospectus supplement
4:13pm
S-4/A
lovsq
9 Nov 22
Registration of securities issued in business combination transactions (amended)
4:31pm
S-4
d251t7rqzpt7jp
26 Oct 22
Registration of securities issued in business combination transactions
9:59pm
425
m3uo44quzlddydzu
26 Sep 22
Business combination disclosure
5:29pm
8-K
EX-99.1
joerb9x8 hlp2bk5xdcp
26 Sep 22
Report of Independent Registered Public Accounting Firm
5:27pm